Peroxisome Proliferator-Activated Receptor β/δ Activation Improves Angiotensin II-Induced Cardiac Hypertrophy in Vitro
Authors:
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 30 (2) , 109-119
Abstract
Agonists of the peroxisome proliferator-activated receptor alpha (PPARα) and gamma (γ) exert anti-proliferative and anti-inflammatory effects that led to the testing of these drugs in experimental cardiac hypertrophy. However, the effect of PPAR beta/delta (β/δ) agonists in hypertrophy is not yet known. In this paper, an experiment was conducted to explore whether PPARβ/δ activation has an effect on cardiac hypertrophy. An in vitro cardiomyocyte hypertrophy from neonatal rats was induced with Angiotensin II (Ang II1μmol·L−1) stimulation. For the examination of PPAR β/δ effect, the cultured rat cardiac myocytes were pretreated with GW0742 (10μmol·L−1), an agonist of PPARβ/δ, for 48h before Ang II stimulation. The following parameters in the cultured cells were determined: surface areas of myocytes were measured by the NIH Image Software; 3H-leucine incorporation into myocytes was counted by liquid scintillometer; mRNA expression of PPARβ/δ, ANP, BNP, MMP9, MMP2, and IL-1β was detected by RT-PCR; PPARβ/δ protein expression was evaluated with immunofluorescence staining; GW0742 could ameliorate Ang II-induced cardiomyocyte hypertrophy, as indicated by its inhibitory effects on the surface area of myocytes, and ANP and BNP mRNA expressions in myocytes and 3H-leucine incorporation into myocytes. Meanwhile, GW0742 pretreatment exerted inhibition on mRNA expression augmentation of such cytokines as MMP9, MMP2, and IL-1β in hypertrophic myocytes. In addition, the down-regulated expression of PPARβ/δ mRNA and protein in hypertrophic myocytes was also significantly reversed by GW0742. We demonstrate for the first time that GW0742 exerts a beneficial effect on Ang II-induced cardiac hypertrophy and the relation to inflammation response.Keywords
This publication has 22 references indexed in Scilit:
- PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytesJournal of Molecular and Cellular Cardiology, 2006
- Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: Implications for multiple sclerosisJournal of Neuroimmunology, 2005
- TGF-?1 and angiotensin networking in cardiac remodelingCardiovascular Research, 2004
- Endothelin-1–Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator–Activated Receptor-α Partly Via Blockade of c-Jun NH 2 -Terminal Kinase PathwayCirculation, 2004
- Peroxisome Proliferator-Activated Receptor (PPAR) α and PPARβ/δ, but not PPARγ, Modulate the Expression of Genes Involved in Cardiac Lipid MetabolismCirculation Research, 2003
- Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In VivoCirculation, 2002
- Medical significance of peroxisome proliferator-activated receptorsThe Lancet, 1999
- Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy.Proceedings of the National Academy of Sciences, 1995
- Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.Circulation Research, 1993
- Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines.Circulation Research, 1982